���ϳԹ���

The U.S. Food and Drug Administration (FDA) granted expanded access for the use of an experimental pancreatic cancer drug, daraxonrasib. This means the drug will be available for early access to those who previously received conventional treatment for metastatic pancreatic ductal adenocarcinoma (PDAC). A healthcare provider must request access to the medication for their patient, according to an FDA statement. (Huynh, 5/4)

A closely watched therapy developed by Johnson & Johnson failed to show a statistically meaningful improvement for patients with inflammatory bowel disease. But the company plans to advance the drug into late-stage testing, focusing on a growing subgroup of patients. (DeAngelis, 5/5)

For Indian billionaire Dilip Shanghvi, who made his fortune selling cheap generic drugs to the world, it was clear at least more than a decade ago that a shift toward specialty treatments would be key to success in the crowded local market. Last week, his firm Sun Pharmaceutical Industries Ltd. announced a $12 billion deal that could be the biggest test yet in the company’s long-brewing bid to transform into an international giant. The company agreed to acquire New Jersey-based Organon & Co. in an all-cash deal that marks one of India’s largest global takeovers and challenges Shanghvi to merge a large, complex business. (Sanjay and Kalesh, 5/5)

Mayo Clinic research published April 28 showed an AI model could detect pancreatic cancer up to three years before clinical diagnosis. Projected to be the second-leading cause of cancer-related death in the U.S. by 2030, early diagnosis has a significant effect on survival outcomes for pancreatic cancer patients. The study from Rochester, Minn.-based Mayo Clinic adds to the larger evidence of AI’s value for cancer detection, but are health systems willing and able to scale these tools? (Gregerson, 5/4)

A common side effect of many GLP-1 drugs is hair loss. It's creating a formerly untapped but growing market for hair treatment products. (Neelakandan, 5/2)

Two years ago, Jennifer Kirtley looked down at the scale and saw 328 pounds. Today, she’s looking in the mirror at a size 6. After a transformative 180-pound weight loss from weekly Wegovy shots, Kirtley says she is happy with her overall weight and health. (Goodman, 5/4)

���ϳԹ��� News: ���ϳԹ��� News’ ‘An Arm and a Leg’: The Supreme Court Case That Could Slow Generic Drugs

The Supreme Court has heard a big case about “skinny labels” on generic drugs. It could shape the future of affordable prescriptions in America. The same medication can be used to treat many conditions. And each use can have its own patent, even though the drug itself never changes. When patents expire, companies can make their own generic versions — but only so long as they make it clear that it can’t be used for anything else that still has a patent. This is what’s called a “skinny label.” (Weissmann, 5/5)

About 1,500 beagles in Wisconsin that have been at the center of a fierce fight waged by animal rights activists are moving to new homes. The state-licensed facility, Ridglan Farms, outside Madison, breeds the beagles for biomedical research aimed at improving veterinary medicine. Last fall, a special prosecutor found that Ridglan had performed procedures on the beagles that constituted animal mistreatment. The company has denied that it abuses animals. (Fortin, 5/4)